Adi on's questions to Moderna Inc (MRNA) leadership • Q2 2025
Question
Adi, on for Cory Kasimov, asked for the rationale behind starting a first-line metastatic melanoma trial for intismarin and about regulatory interactions regarding the path forward for the checkpoint program.
Answer
President Stephen Hoge stated that strong data from the adjuvant melanoma study and manufacturing advancements prompted the expansion into metastatic disease. For the checkpoint program, he confirmed early-stage regulatory discussions are underway, but the 2028 filing target primarily reflects internal prioritization and conviction in the program's potential.